scholarly journals Cardiac Troponin I Associated with Poor Prognosis and Death Risk in 726 Severe and Critical COVID-19 Patients: A Retrospective Cohort Study

2020 ◽  
Author(s):  
Huilong Chen ◽  
Xinjie Li ◽  
Tuohutaerbieke Marmar ◽  
Qiang Xu ◽  
Jing Tu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiac Troponin ◽  
Poor Prognosis ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Critical Group ◽  
Advanced Age ◽  
Factors Associated ◽  
Severe Group ◽  
Ctni Level

Abstract Background: A few patients with coronavirus disease 2019 (COVID-19) may progress into irreparable outcomes. Early identification of patients with serious symptoms who may develop critical illness and even death is of considerable importance for personalizing treatment and balancing medical resources.Methods: In this retrospective study, demographic, clinical characteristics and laboratory tests from 726 patients with serious COVID-19 from Tongji Hospital (Wuhan, China) were analyzed. The standards for the serious type are guided by the Chinese management guideline for COVID-19. Patients were classified into critical group (174 cases) and severe group (552 cases) based on whether the composite endpoint was reached, and the former group was divided into the survivors (47 cases) and non-survivors (127 cases). Univariable and multivariable logistic regression and receiver operating characteristic (ROC) curve analysis were performed to investigate the risk factors associated with poor prognosis and mortality outcomes.Results: Male patients accounted for 62.1% and 51.6% in the critical group and severe group, with a median age of 68 and 65 years, respectively. Among critical cases there was a higher prevalence of chronic obstructive lung disease (p = 0.029) and chest distress (p = 0.040) than in severe cases. In the multivariable analysis, the risk factors associated with poor prognosis in severe cases were advanced age (p = 0.002), high respiratory rate (RR) (p < 0.0001), high lactate dehydrogenase (LDH) level (p = 0.021), high hypersensitive cardiac troponin I (hs-cTnI) level (p < 0.0001), and low platelet counts (p = 0.005) at admission. In the adjusted models, higher mortality outcomes in critical patients were associated with high hs-cTnI level (p = 0.037). By plotting ROC curves of different indices, hs-cTnI and LDH were found to be predictive factors for poor prognosis in patients with severe COVID-19.Conclusions: For the risk assessment of serious COVID-19 patients on admission, advanced age, high level of RR, LDH, hs-cTnI, and low platelet counts, constitute important risk factors for poor prognosis in severe cases, and the hs-cTnI level can be helpful in predicting fatal outcomes in critically ill patients.

scholarly journals Postoperative Cardiac Troponin I (cTnI) Level and Its Prognostic Value for Patients Undergoing Mitral Valve Surgery

2010 ◽  
Vol 51 (3) ◽  
pp. 166-169 ◽  
Author(s):  
Kiyohiro Oshima ◽  
Fumio Kunimoto ◽  
Toru Takahashi ◽  
Jun Mohara ◽  
Izumi Takeyoshi ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Cardiac Troponin ◽  
Prognostic Value ◽  
Troponin I ◽  
Mitral Valve Surgery ◽  
Valve Surgery ◽  
Cardiac Troponin I ◽  
Ctni Level

scholarly journals Factors associated with increased levels of brain natriuretic peptide and cardiac troponin I during the peripartum period

PLoS ONE ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. e0211982
Author(s):  
Yuki Kimura ◽  
Takao Kato ◽  
Hiromi Miyata ◽  
Issei Sasaki ◽  
Eri Minamino-Muta ◽  
...  
Keyword(s):  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Factors Associated ◽  
Peripartum Period

scholarly journals Pre-cardiopulmonary bypass administration of dexmedetomidine decreases cardiac troponin I level following cardiac surgery with sevoflurane postconditioning

2019 ◽  
Vol 47 (8) ◽  
pp. 3623-3635
Author(s):  
Hong-mei Zhou ◽  
Xiao-yan Ling ◽  
Yun-jian Ni ◽  
Cheng Wu ◽  
Zhi-peng Zhu
Keyword(s):  
New York ◽  
Cardiac Surgery ◽  
Cardiopulmonary Bypass ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Myocardial Damage ◽  
Heart Association ◽  
Cardiac Troponin I ◽  
Sevoflurane Postconditioning ◽  
Ctni Level

Objective This study was performed to determine the effect of dexmedetomidine (DEX) administration on myocardial damage in cardiac surgery with sevoflurane postconditioning. Methods We retrospectively examined all cardiac valve replacement surgeries from 1 April 2016 to 30 April 2017. Eligible patients were divided into two groups based on whether DEX was infused. DEX infusion was permitted only between intubation and the beginning of cardiopulmonary bypass (CPB). Sevoflurane was inhaled via the standard postconditioning procedure starting at aortic declamping. The cardiac troponin I (cTnI) level was measured at different time points. The postoperative outcomes and complications were also analyzed. Results One hundred patients were included in the study (DEX group, n = 53; non-DEX group, n = 47). Increased cTnI levels were significantly correlated with the New York Heart Association classification, CPB time, and DEX use. DEX use and the CPB time were potential independent factors contributing to changes in the cTnI level. The cTnI level at 6, 12, and 24 hours postoperatively was remarkably lower in the DEX than non-DEX group by 1.14, 7.83, and 5.86 ng/mL, respectively. Conclusions DEX decreased the cTnI level after CPB when sevoflurane postconditioning was used, especially at 6, 12, and 24 hours postoperatively.

scholarly journals High-Sensitivity Cardiac Troponin-I Is Elevated in Patients with Rheumatoid Arthritis, Independent of Cardiovascular Risk Factors and Inflammation

PLoS ONE ◽  
2012 ◽  
Vol 7 (6) ◽  
pp. e38930 ◽  
Author(s):  
William S. Bradham ◽  
Aihua Bian ◽  
Annette Oeser ◽  
Tebeb Gebretsadik ◽  
Ayumi Shintani ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Cardiac Troponin ◽  
Troponin I ◽  
High Sensitivity ◽  
Cardiac Troponin I

scholarly journals Developing Sensitive Golden Plate Biosensor for Early Detection of Serum Cardiac Troponin I as Diagnostic Biomarkers

2018 ◽  
Author(s):  
Said Moselhy ◽  
Ehab Mostafa ◽  
Abdulrahman Almalki ◽  
Taha Kumosani ◽  
Youssri Soliman ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Cardiac Troponin ◽  
Healthy Subjects ◽  
Large Scale ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Diagnostic Biomarkers ◽  
Elisa Technique ◽  
Serum Cardiac Troponin ◽  
Ctni Level

Rapid diagnosis of acute myocardial infarction is critical for intervention and treatment to decrease morbidity and mortality. For this reasons, this study aimed to design a sensitive biosensor for cardiac troponin I (cTnI) for early prediction and intervention. The sensor was designed from golden plate immobilized with anti- cTnI antibody conjugated with horseradish peroxidase (HRP) enzyme. The rate of degradation of H2O2 is directly related to serum cTnI level. Serum cTnI level was quantified from 3 studied groups including; healthy subjects and patients with ischemic heart (IHD) diseases and myocardial infarction (MI) by ELISA and biosensor techniques to achieve the improved sensitivity of the biosensor. It was found that cTnI levels in healthy subjects ranged from 8-13 ng/dl and in patients with IHD ranged from 20 - 41 ng/dl and MI range from 57- 180 ng/dl. The sensitivity of biosensor was ranged from 85-95% compared with ELISA technique. The developed biosensor is promising in ICU hospitals for early diagnosis and prevent complications of the stroke. It is recommended to apply this biosensor in the large scale of patients with different stages of the cardiac disease.

scholarly journals Cardiac troponin I (CTnI) level among children with epileptic seizures

2014 ◽  
Vol 66 (3) ◽  
pp. 277-282 ◽  
Author(s):  
Ahmed Anwer Attia Khattab ◽  
Sameh Abdallah Abd-Elnaby ◽  
Ashrf Abd-Elraaof Dwood ◽  
Maha Attia Hagras
Keyword(s):  
Cardiac Troponin ◽  
Troponin I ◽  
Epileptic Seizures ◽  
Cardiac Troponin I ◽  
Ctni Level

Data mining: Biological and temporal factors associated with blood cardiac troponin I concentration in a Chinese population

2019 ◽  
Vol 495 ◽  
pp. 8-12 ◽  
Author(s):  
Dandan Li ◽  
Danying Wang ◽  
Danchen Wang ◽  
Chaochao Ma ◽  
Jie Wu ◽  
...  
Keyword(s):  
Data Mining ◽  
Cardiac Troponin ◽  
Chinese Population ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Factors Associated ◽  
Temporal Factors

Predictors of In-Hospital Mortality in Patients Receiving Thrombolytic Therapy for Pulmonary Embolism

2011 ◽  
Vol 17 (6) ◽  
pp. 656-658 ◽  
Author(s):  
Haroon L. Chughtai ◽  
Muhammad Janjua ◽  
Fadi Matta ◽  
Fadel Jaweesh ◽  
Paul D. Stein
Keyword(s):  
Risk Factors ◽  
Pulmonary Embolism ◽  
Thrombolytic Therapy ◽  
Hospital Mortality ◽  
Right Ventricle ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Massive Pulmonary Embolism ◽  
Cardiac Troponin I

Predictors of in-hospital mortality from massive pulmonary embolism (PE) were retrospectively assessed in 78 patients who received thrombolytic therapy. Mortality from PE was 19% (15 of 78). Mortality from PE was higher in those with shock, 36% (12 of 33) versus no shock, 7% (3 of 45; P = .001), 21% (7 of 34) with right ventricle (RV) hypokinesis, and 20% (13 of 64) with RV enlargement. Mortality was 14% (2 of 14) with normal cardiac troponin I (cTnI), 19% (4 of 21) with intermediate cTnI, and 22% (8 of 36) with high cTnI (comparisons between groups nonsignificant [NS]). Trends with combinations of risk factors showed the highest mortality with shock plus high cTnI plus RV hypokinesis (57%) or shock plus high cTnI plus RV enlargement (54%). In conclusion, among the single risk factors, shock was associated with the highest in-hospital mortality from PE and combinations with high cTnI and RV enlargement were associated with higher mortalities.

scholarly journals High-Sensitivity Cardiac Troponin I Is a Strong Predictor of Cardiovascular Events and Mortality in the AGES-Reykjavik Community-Based Cohort of Older Individuals

2016 ◽  
Vol 62 (4) ◽  
pp. 623-630 ◽  
Author(s):  
Ingunn Thorsteinsdottir ◽  
Thor Aspelund ◽  
Elias Gudmundsson ◽  
Gudny Eiriksdottir ◽  
Tamara B Harris ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Disease ◽  
Cardiac Troponin ◽  
Cardiovascular Events ◽  
Troponin I ◽  
Strong Predictor ◽  
Large Population ◽  
High Sensitivity ◽  
Cardiac Troponin I ◽  
Conventional Risk Factors

Abstract BACKGROUND The objective of this study was to investigate the predictive power of a high-sensitivity cardiac troponin I (hs-cTnI) assay for cardiovascular events and mortality in a large population of older community dwellers. METHODS Blood was collected from 5764 individuals (age 66–98 years) during the period of 2002–2006 and the outcome as to all-cause death and incidence of cardiovascular disease (CVD) and coronary heart disease (CHD) followed up to 10 years. hs-cTnI (Abbott) was measured in serum to assess the association of this marker with CVD, CHD and death, and finally, to compare the results with conventional risk factors by multivariable statistical analysis. RESULTS The median (interquartile range) concentrations of hs-cTnI were 8.4 ng/L (5.6–14.2 ng/L) and 5.3 ng/L (3.8–8.1 ng/L) in men (2416) and women (3275), respectively, and the concentrations increased linearly with age. Outcomes as to all-cause death and incidence of CVD and CHD were significantly associated with increasing concentrations of hs-cTnI beginning well below the 99th percentile concentrations. The associations with outcome remained after adjustments for conventional risk factors and were similar in men and women. CONCLUSIONS Our findings suggest that hs-cTnI reflects the status of the myocardium even in seemingly healthy individuals and that the measurements of hs-cTnI may be useful for primary prediction of heart disease; this should form the basis for future prospective clinical trials for determining whether measuring hs-cTnI can be used in the prevention of CVD/CHD.

scholarly journals Prognostic Value of Troponin I in COVID-19 Patients

2021 ◽  
Vol 15 (1) ◽  
pp. 18-22
Author(s):  
Alaa A. Ghaleb ◽  
Ahmed Sadky ◽  
Mohammed A. Meghaizel ◽  
Shehab El Etriby
Keyword(s):  
Cardiac Troponin ◽  
Prognostic Value ◽  
Troponin I ◽  
Virus Disease ◽  
Cardiac Troponin I ◽  
Icu Admission ◽  
Acute Myocardial Injury ◽  
A Prospective Study ◽  
Electrocardiogram Ecg ◽  
Ctni Level

Introduction: Corona Virus Disease (COVID -19) patients present mainly with respiratory manifestations and viral pneumonia. The cardiovascular system presentation includes early signs of acute myocardial injury. Cardiac troponin I (cTnI) is a gold-standard biomarker for necrosis and myocardial risk assessment. Aim of the work: This study aimed to assess the prognostic value of cTnI in COVID-19 patients. Methodology: We report a prospective study that included 92 COVID-19 patients admitted to the El Helal Hospital, Sohag, Egypt. Upon admission, routine investigations including cTnI, chest Computed Tomography (CT), and Electrocardiogram (ECG) were carried out. The patients admitted to the intensive care unit (ICU) also had echocardiography. Results: More than half of the patients (55.4%) were admitted to ICU; cTnI level was elevated in 30 patients (58.8%), of whom 17 died (56.7%). There were statistically significant differences regarding the relation between cTnI level, D-dimer and the need for ICU admission and death (p=0.001). Conclusion: We conclude that cardiac troponin I levels are a prognostic factor for ICU admission and mortality in COVID-19 patients.

Sign in / Sign up

Export Citation Format

Share Document